Global Hematopoietic Agents Market Size, Share, and Trends Analysis Report – Industry Overview and Forecast to 2033

Hematopoietic Agents Market Size

• The global Hematopoietic Agents market size was valued at USD 45.00 billion in 2025and is expected to reach USD 80.25 billion by 2033, at a CAGR of 7.50% during the forecast period
• The market growth is largely fueled by the increasing prevalence of blood disorders such as anemia, leukemia, and neutropenia, leading to rising demand for advanced blood cell–stimulating therapies across hospitals and specialty clinics
• Furthermore, growing advancements in biologics, increasing adoption of targeted hematology treatments, and rising focus on improving patient outcomes in oncology and hematology care are establishing growth factor–based therapies as a preferred treatment approach for Hematopoietic Agents. These converging factors are accelerating the uptake of Hematopoietic Agents solutions, thereby significantly boosting the industry's growth

Hematopoietic Agents Market Analysis

• Hematopoietic Agents are increasingly vital in oncology, hematology, and supportive cancer care due to their role in stimulating red and white blood cell production, improving patient recovery, and reducing complications associated with chemotherapy and bone marrow disorders
• The escalating demand for hematopoietic agents is primarily fueled by the rising prevalence of cancer, anemia, and chronic kidney diseases, along with increasing use of chemotherapy and growing adoption of supportive care biologics in hospital settings
• North America dominated the hematopoietic agents market with the largest revenue share of 42.8% in 2025, characterized by advanced healthcare infrastructure, strong oncology treatment adoption, high healthcare spending, and the presence of major pharmaceutical companies, with the U.S. experiencing substantial growth in hematology treatments driven by increasing cancer incidence and expanded use of biologic growth factors
• Asia-Pacific is expected to be the fastest growing region in the Hematopoietic Agents market during the forecast period due to rising cancer burden, improving healthcare infrastructure, increasing awareness of supportive care therapies, and expanding access to biologic drugs in emerging economies
• The agents for anemia segment dominated the largest market revenue share of 54.3% in 2025, driven by the high global prevalence of anemia caused by iron deficiency, chronic diseases, and nutritional disorders

Report Scope and Hematopoietic Agents Market Segmentation

Hematopoietic Agents Market Trends

“Increasing Focus on Precision Medicine and Targeted Therapeutic Innovations”

• A significant and rapidly evolving trend in the global Hematopoietic Agents market is the growing emphasis on precision medicine and targeted therapeutic innovations aimed at improving hematologic disease outcomes and minimizing treatment-related complications
• Pharmaceutical companies are increasingly focusing on developing next-generation hematopoietic agents, including erythropoiesis-stimulating agents (ESAs), colony-stimulating factors (CSFs), and thrombopoietin receptor agonists that provide more targeted and effective management of blood-related disorders
• For instance, ongoing advancements in biologics and recombinant DNA technology are enabling the development of safer and more effective hematopoietic therapies with improved efficacy and reduced immunogenicity
• The integration of biomarker-based diagnostics is further supporting personalized treatment approaches by helping clinicians determine optimal dosing, predict treatment response, and reduce adverse effects in patients with anemia, neutropenia, and thrombocytopenia
• Furthermore, the rising adoption of advanced drug delivery systems is improving treatment efficiency, patient compliance, and therapeutic outcomes in chronic hematological conditions
• Increasing clinical research activities and expanding regulatory approvals for novel hematopoietic therapies are accelerating innovation and broadening the treatment landscape globally
• This shift toward targeted biologics, personalized medicine, and advanced therapeutic formulations is significantly transforming the Hematopoietic Agents market and improving patient care outcomes worldwide

Hematopoietic Agents Market Dynamics

Driver

“Growing Need Due to Rising Prevalence of Blood Disorders and Increasing Oncology Treatments”

• The increasing prevalence of blood-related disorders such as anemia, neutropenia, thrombocytopenia, and bone marrow suppression is a major factor driving the growth of the global Hematopoietic Agents market
• Rising incidences of cancer and the growing use of chemotherapy and radiotherapy are significantly increasing the demand for hematopoietic agents to manage treatment-induced myelosuppression and improve patient recovery outcomes
• For instance, the expanding global cancer burden has led to increased utilization of supportive care therapies, including ESAs and CSFs, to reduce infection risks and improve quality of life in oncology patients
• Furthermore, the growing aging population, which is more susceptible to chronic hematological conditions and immune system decline, is contributing to increased demand for hematopoietic treatments
• Advancements in biotechnology and pharmaceutical research are enabling the development of more effective and safer hematopoietic agents with improved therapeutic profiles and reduced side effects
• In addition, increasing healthcare expenditure, improved access to diagnostic services, and rising awareness regarding early treatment of blood disorders are supporting market growth globally
• Government initiatives supporting rare disease treatment and oncology care are also contributing to the expansion of the Hematopoietic Agents market across developed and emerging regions

Restraint/Challenge

“High Treatment Costs and Safety-Related Concerns”

• The high cost associated with advanced hematopoietic therapies, particularly biologics and long-acting formulations, remains a significant challenge restraining the growth of the Hematopoietic Agents market
• Long-term treatment requirements for chronic blood disorders and cancer-related complications can impose substantial financial burdens on patients and healthcare systems, especially in low- and middle-income countries
• For instance, certain erythropoiesis-stimulating agents and colony-stimulating factors involve high production costs, which can limit accessibility and affordability for a large patient population
• In addition, safety concerns associated with long-term use of hematopoietic agents, such as increased risk of thromboembolic events or potential stimulation of tumor progression in certain cases, may limit their widespread adoption
• The need for continuous monitoring, dose adjustments, and strict clinical supervision also adds complexity to treatment management and increases healthcare resource utilization
• Furthermore, variability in reimbursement policies and limited insurance coverage for some hematopoietic therapies can restrict patient access in several regions
• Addressing these challenges through cost-effective drug development, improved safety profiles, enhanced clinical guidelines, and broader reimbursement support will be essential for sustaining long-term growth in the global Hematopoietic Agents market

Hematopoietic Agents Market Scope

The market is segmented on the basis of class, indications, route of administration, end-users, and distribution channel.

• By Class

On the basis of class, the Hematopoietic Agents market is segmented into agents for anemia, hematopoietic growth factors, and others. The agents for anemia segment dominated the largest market revenue share of 54.3% in 2025, driven by the high global prevalence of anemia caused by iron deficiency, chronic diseases, and nutritional disorders. These agents, including iron supplements, erythropoiesis-stimulating agents, and vitamin-based therapies, are widely used in routine clinical practice to restore hemoglobin levels and improve oxygen transport. Increasing awareness regarding early diagnosis of anemia and rising screening programs are significantly contributing to segment growth. Physicians frequently prescribe anemia management agents for long-term supportive care in chronic kidney disease and cancer-related anemia. In addition, growing healthcare access in developing regions and improved availability of generic formulations are strengthening market expansion. Rising burden of lifestyle-related disorders and pregnancy-associated anemia further supports segment dominance globally.

The hematopoietic growth factors segment is anticipated to witness the fastest growth rate of 22.8% from 2026 to 2033, driven by increasing use in oncology, bone marrow disorders, and post-chemotherapy recovery support. These agents stimulate blood cell production and are widely used in managing neutropenia and thrombocytopenia in cancer patients. Rising prevalence of cancer and expanding use of chemotherapy and radiotherapy are significantly contributing to segment growth. In addition, advancements in recombinant DNA technology and biologic drug development are accelerating adoption. Growing clinical preference for targeted therapies and supportive care biologics is further boosting demand. Expanding research in regenerative medicine and hematology is also expected to drive long-term market expansion.

• By Indications

On the basis of indications, the Hematopoietic Agents market is segmented into iron deficiency anemia, megaloblastic anemia, hematopoietic growth factors disorders, and others. The iron deficiency anemia segment held the largest market revenue share of 47.6% in 2025, driven by its high global prevalence across all age groups, particularly among women, children, and elderly populations. Iron deficiency anemia is commonly associated with poor nutrition, chronic blood loss, and increased physiological demand. Rising awareness regarding early diagnosis and routine screening programs is significantly supporting segment growth globally. Physicians widely prescribe oral and parenteral iron therapies as first-line treatment options. In addition, government-led nutrition improvement programs and fortification initiatives are strengthening market demand. Increasing healthcare access and availability of cost-effective iron supplements are further contributing to segment dominance.

The hematopoietic growth factors disorders segment is expected to witness the fastest CAGR of 23.2% from 2026 to 2033, driven by increasing incidence of bone marrow suppression and chemotherapy-induced blood disorders. Growing use of biologics such as erythropoietin and colony-stimulating factors is significantly improving patient outcomes. Advancements in biotechnology and expanding oncology treatment protocols are further supporting segment growth. Rising prevalence of cancer and hematologic disorders is accelerating demand for targeted hematopoietic therapies. Increasing clinical adoption of supportive care treatments in hospitals and specialty centers is also expected to boost market expansion during the forecast period.

• By Route of Administration

On the basis of route of administration, the Hematopoietic Agents market is segmented into oral, parenteral, and others. The oral segment dominated the largest market revenue share of 51.8% in 2025, driven by the widespread use of oral iron supplements, vitamins, and anemia management drugs. Oral administration is highly preferred due to ease of use, cost-effectiveness, and strong patient compliance in long-term therapy. Increasing prevalence of mild to moderate anemia cases managed through outpatient care is significantly contributing to segment growth. Physicians commonly prescribe oral hematopoietic agents as first-line therapy for iron deficiency and nutritional anemia. In addition, expanding availability of over-the-counter formulations is further supporting market expansion. Rising awareness regarding preventive healthcare and routine supplementation is also strengthening demand globally.

The parenteral segment is anticipated to witness the fastest CAGR of 22.5% from 2026 to 2033, driven by increasing use of intravenous iron therapy and injectable hematopoietic growth factors. Parenteral administration is preferred in severe anemia cases, chronic kidney disease patients, and individuals with poor gastrointestinal absorption. Advancements in infusion technologies and improved safety profiles of injectable formulations are supporting segment growth. In addition, rising hospital admissions for chronic diseases and oncology treatments is further accelerating adoption. Growing demand for rapid therapeutic response and improved patient outcomes is also expected to drive segment expansion during the forecast period.

• By End-Users

On the basis of end-users, the Hematopoietic Agents market is segmented into hospitals, homecare, specialty centres, and others. The hospitals segment accounted for the largest market revenue share of 49.1% in 2025, driven by the high volume of anemia diagnosis, cancer treatment, and chronic disease management conducted in hospital settings. Hospitals are the primary centers for administering injectable hematopoietic agents and managing severe cases requiring continuous monitoring. Increasing prevalence of cancer and chronic kidney diseases is significantly contributing to segment growth globally. In addition, hospitals offer advanced diagnostic facilities and specialized hematology departments, ensuring effective treatment outcomes. Government investments in healthcare infrastructure and expansion of tertiary care centers further support market dominance. The availability of skilled healthcare professionals and integrated treatment systems also strengthens hospital-based care adoption.

The specialty centres segment is expected to witness the fastest CAGR of 21.9% from 2026 to 2033, driven by increasing demand for specialized hematology and oncology care services. These centers provide focused treatment for blood disorders using advanced therapeutic approaches and personalized medicine. Rising preference for outpatient specialty care and reduced hospital burden is contributing to segment growth. In addition, expanding private specialty clinics and increasing awareness regarding targeted therapies are further accelerating adoption. Technological advancements in diagnostic and treatment modalities are also supporting market expansion during the forecast period.

• By Distribution Channel

On the basis of distribution channel, the Hematopoietic Agents market is segmented into hospital pharmacy, online pharmacy, and retail pharmacy. The hospital pharmacy segment held the largest market revenue share of 52.4% in 2025, driven by the high utilization of prescription-based hematopoietic agents in hospital settings. Hospital pharmacies play a critical role in dispensing injectable therapies, biologics, and high-cost anemia treatments under medical supervision. Increasing hospitalization rates for chronic diseases and oncology treatments are significantly contributing to segment growth. In addition, integrated hospital pharmacy systems ensure proper drug management and patient safety. Favorable reimbursement policies for hospital-administered therapies further strengthen segment dominance globally. Expanding healthcare infrastructure and rising demand for specialized treatments are also supporting market expansion.

The online pharmacy segment is anticipated to witness the fastest CAGR of 23.6% from 2026 to 2033, driven by rapid digitalization of healthcare and increasing preference for convenient medication access. Online platforms offer benefits such as home delivery, subscription-based refills, and competitive pricing for long-term anemia management drugs. Rising internet penetration and smartphone usage are significantly supporting adoption of e-pharmacy services. Patients increasingly prefer online channels for repeat prescriptions due to convenience and cost savings. In addition, supportive regulatory frameworks and advancements in digital healthcare ecosystems are accelerating market growth globally.

Hematopoietic Agents Market Regional Analysis

• North America dominated the hematopoietic agents market with the largest revenue share of 42.8% in 2025, characterized by advanced healthcare infrastructure, strong oncology treatment adoption, high healthcare spending, and the presence of major pharmaceutical companies. The region is witnessing significant growth in hematology and oncology treatments, driven by the increasing incidence of cancer and expanding use of biologic growth factors and supportive care therapies
• The market growth is further supported by rising demand for advanced cancer care, increasing adoption of targeted biologics, and strong clinical research activities focused on hematopoietic disorders and oncology supportive treatments. In addition, favorable reimbursement frameworks and early access to innovative therapies are accelerating market expansion across North America
• The presence of leading pharmaceutical manufacturers, well-established hospital networks, and robust R&D investment in hematology and oncology continues to strengthen North America’s leadership position in the Hematopoietic Agents market

U.S. Hematopoietic Agents Market Insight

The U.S. hematopoietic agents market captured the largest revenue share in 2025 within North America, fueled by the rising burden of cancer and blood-related disorders, along with strong adoption of biologic growth factors and hematopoietic therapies. The country is experiencing substantial growth in oncology supportive care treatments, supported by increasing clinical trials and rapid regulatory approvals for innovative biologic drugs. Furthermore, strong healthcare expenditure, advanced treatment infrastructure, and growing integration of precision medicine in oncology are contributing significantly to market expansion in the U.S.

Europe Hematopoietic Agents Market Insight

The Europe hematopoietic agents market is projected to expand at a substantial CAGR throughout the forecast period, primarily driven by increasing cancer prevalence and rising demand for advanced supportive care therapies. The region benefits from strong healthcare systems, supportive regulatory frameworks for biologic drugs, and increasing investments in oncology research. In addition, growing adoption of biosimilars and expanding access to hematology treatments are supporting market growth across Europe.

U.K. Hematopoietic Agents Market Insight

The U.K. hematopoietic agents market is anticipated to grow at a noteworthy CAGR during the forecast period, driven by increasing cancer incidence and rising use of supportive oncology treatments. The country’s strong public healthcare system and growing focus on improving cancer care outcomes are supporting adoption of hematopoietic therapies. Moreover, increasing clinical research activity and expanding access to biologic drugs are further contributing to market growth in the U.K.

Germany Hematopoietic Agents Market Insight

The Germany hematopoietic agents market is expected to expand at a considerable CAGR during the forecast period, fueled by advanced oncology infrastructure and strong emphasis on innovative biologic therapies. Germany’s robust pharmaceutical industry and increasing adoption of hematology and oncology supportive care treatments are supporting market expansion. Furthermore, rising investments in cancer research and increasing availability of biosimilars are enhancing treatment accessibility across the country.

Asia-Pacific Hematopoietic Agents Market Insight

The Asia-Pacific hematopoietic agents market is expected to be the fastest growing region during the forecast period due to rising cancer burden, improving healthcare infrastructure, increasing awareness of supportive care therapies, and expanding access to biologic drugs in emerging economies. Rapid healthcare development in countries such as China, India, and Japan is enabling wider availability of hematology treatments. In addition, growing government initiatives for cancer care improvement and increasing healthcare expenditure are driving strong regional market growth.

Japan Hematopoietic Agents Market Insight

The Japan hematopoietic agents market is gaining momentum due to the country’s aging population, increasing cancer prevalence, and advanced healthcare system. Japan’s strong focus on precision medicine and biologic therapies is supporting the adoption of hematopoietic agents in oncology and hematology care. Moreover, increasing availability of advanced treatment options and growing clinical research in cancer supportive care are contributing to market expansion.

China Hematopoietic Agents Market Insight

The China hematopoietic agents market accounted for the largest market revenue share in Asia-Pacific in 2025, attributed to the country’s rising cancer burden, expanding healthcare infrastructure, and increasing access to biologic therapies. China is witnessing strong growth in oncology and hematology treatment adoption, supported by rising healthcare investments and expanding hospital networks. In addition, government initiatives aimed at improving cancer care, along with increasing availability of affordable biologic drugs, are key factors propelling market growth in the country.

Hematopoietic Agents Market Share

The Hematopoietic Agents industry is primarily led by well-established companies, including:

• Amgen Inc. (U.S.)
• Pfizer Inc. (U.S.)
• Novartis AG (Switzerland)
• Hoffmann-La Roche Ltd. (Switzerland)
• Johnson & Johnson (U.S.)
• Sanofi (France)
• Bristol Myers Squibb (U.S.)
• Merck & Co., Inc. (U.S.)
• AbbVie Inc. (U.S.)
• AstraZeneca (U.K.)
• GSK plc (U.K.)
• Takeda Pharmaceutical Company Limited (Japan)
• Kyowa Kirin Co., Ltd. (Japan)
• Teva Pharmaceutical Industries Ltd. (Israel)
• Cipla Limited (India)
• Sun Pharmaceutical Industries Ltd. (India)
• Reddy’s Laboratories Ltd. (India)
• Viatris Inc. (U.S.)
• Biocon Limited (India)
• Sandoz Group AG (Switzerland)

Latest Developments in Global Hematopoietic Agents Market

• In March 2021, FibroGen and AstraZeneca faced regulatory setbacks when the U.S. FDA issued a complete response letter for roxadustat, a first-in-class oral hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI) for anemia of chronic kidney disease. The decision impacted the competitive landscape of erythropoiesis-stimulating therapies globally
• In August 2021, the U.S. FDA rejected approval of roxadustat for anemia in chronic kidney disease, reinforcing continued reliance on established erythropoiesis-stimulating agents (ESAs) such as epoetin alfa and darbepoetin alfa in global treatment protocols
• In February 2023, the U.S. FDA approved Jesduvroq (daprodustat), the first oral hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI) for anemia due to chronic kidney disease in dialysis patients, marking a major shift away from injectable erythropoiesis-stimulating agents
• In November 2023, the U.S. FDA approved Ryzneuta (efbemalenograstim alfa-vuxw), a long-acting granulocyte colony-stimulating factor (G-CSF), to reduce the incidence of infection in patients with chemotherapy-induced neutropenia. This expanded the long-acting hematopoietic growth factor market
• In March 2024, the European Medicines Agency approved efbemalenograstim alfa, further expanding the availability of long-acting G-CSF therapies used to stimulate neutrophil production in oncology patients undergoing chemotherapy
• In June 2024, the U.S. FDA approved imetelstat (Rytelo) for treatment of transfusion-dependent anemia in lower-risk myelodysplastic syndromes (MDS), representing a first-in-class telomerase inhibitor that targets abnormal hematopoiesis
• In May 2025, the U.S. FDA approved belzutifan (Welireg) expansion for additional oncology indications, highlighting growing integration of hypoxia-inducible pathway modulators in hematologic and anemia-related supportive care ecosystems

SKU-55256